Dr Alexander Maytum
Dr Alexander Maytum
Dr Alexander Maytum is a Research Officer at the Murdoch Children’s Research Institute, working with Professor Andrew Elefanty in the field of blood development. With a strong background in cell biology, genomics and bioinformatics, Alex is dedicated to understanding the molecular mechanisms that drive lineage commitment in blood cell differentiation.
Alex completed a BSc at Durham University and an MSc at Imperial College London. Following this Alex worked on cancer clinical trials at the University College London Medical Research Council Clinical Trials Unit and then on vaccine clinical trials at the University of Oxford Oxford Vaccine Group. Alex completed his PhD in Cancer and Genomic Sciences under the supervision of Professor Constanze Bonifer at the University of Birmingham.
Currently, Alex focuses on the genome-wide study of how transcription factors, in response to signalling, drive lineage commitment in differentiating embryonic stem cells and induced pluripotent stem cells (iPSCs) into blood cell lineages. With expertise in both wet-lab techniques and bioinformatics—including big data analysis, gene regulatory network construction, and AI-based approaches Alex combines experimental and computational methodologies to uncover key mechanisms in hematopoietic development. Alex also has a strong interest in the aetiology of acute myeloid leukaemia. One of Alex’s key research interests lies in the role of signalling factors such as VEGF in the development of the blood, particularly how VEGF signalling represses RUNX1 expression, blocking the full commitment to hematopoietic stem cells. His work aims to provide deeper insights into blood cell formation and identify potential therapeutic targets for haematological disorders.
Alex completed a BSc at Durham University and an MSc at Imperial College London. Following this Alex worked on cancer clinical trials at the University College London Medical Research Council Clinical Trials Unit and then on vaccine clinical trials at the University of Oxford Oxford Vaccine Group. Alex completed his PhD in Cancer and Genomic Sciences under the supervision of Professor Constanze Bonifer at the University of Birmingham.
Currently, Alex focuses on the genome-wide study of how transcription factors, in response to signalling, drive lineage commitment in differentiating embryonic stem cells and induced pluripotent stem cells (iPSCs) into blood cell lineages. With expertise in both wet-lab techniques and bioinformatics—including big data analysis, gene regulatory network construction, and AI-based approaches Alex combines experimental and computational methodologies to uncover key mechanisms in hematopoietic development. Alex also has a strong interest in the aetiology of acute myeloid leukaemia. One of Alex’s key research interests lies in the role of signalling factors such as VEGF in the development of the blood, particularly how VEGF signalling represses RUNX1 expression, blocking the full commitment to hematopoietic stem cells. His work aims to provide deeper insights into blood cell formation and identify potential therapeutic targets for haematological disorders.
Dr Alexander Maytum is a Research Officer at the Murdoch Children’s Research Institute, working with Professor Andrew Elefanty in the field of blood development. With a strong background in cell biology, genomics and bioinformatics, Alex is...
Dr Alexander Maytum is a Research Officer at the Murdoch Children’s Research Institute, working with Professor Andrew Elefanty in the field of blood development. With a strong background in cell biology, genomics and bioinformatics, Alex is dedicated to understanding the molecular mechanisms that drive lineage commitment in blood cell differentiation.
Alex completed a BSc at Durham University and an MSc at Imperial College London. Following this Alex worked on cancer clinical trials at the University College London Medical Research Council Clinical Trials Unit and then on vaccine clinical trials at the University of Oxford Oxford Vaccine Group. Alex completed his PhD in Cancer and Genomic Sciences under the supervision of Professor Constanze Bonifer at the University of Birmingham.
Currently, Alex focuses on the genome-wide study of how transcription factors, in response to signalling, drive lineage commitment in differentiating embryonic stem cells and induced pluripotent stem cells (iPSCs) into blood cell lineages. With expertise in both wet-lab techniques and bioinformatics—including big data analysis, gene regulatory network construction, and AI-based approaches Alex combines experimental and computational methodologies to uncover key mechanisms in hematopoietic development. Alex also has a strong interest in the aetiology of acute myeloid leukaemia. One of Alex’s key research interests lies in the role of signalling factors such as VEGF in the development of the blood, particularly how VEGF signalling represses RUNX1 expression, blocking the full commitment to hematopoietic stem cells. His work aims to provide deeper insights into blood cell formation and identify potential therapeutic targets for haematological disorders.
Alex completed a BSc at Durham University and an MSc at Imperial College London. Following this Alex worked on cancer clinical trials at the University College London Medical Research Council Clinical Trials Unit and then on vaccine clinical trials at the University of Oxford Oxford Vaccine Group. Alex completed his PhD in Cancer and Genomic Sciences under the supervision of Professor Constanze Bonifer at the University of Birmingham.
Currently, Alex focuses on the genome-wide study of how transcription factors, in response to signalling, drive lineage commitment in differentiating embryonic stem cells and induced pluripotent stem cells (iPSCs) into blood cell lineages. With expertise in both wet-lab techniques and bioinformatics—including big data analysis, gene regulatory network construction, and AI-based approaches Alex combines experimental and computational methodologies to uncover key mechanisms in hematopoietic development. Alex also has a strong interest in the aetiology of acute myeloid leukaemia. One of Alex’s key research interests lies in the role of signalling factors such as VEGF in the development of the blood, particularly how VEGF signalling represses RUNX1 expression, blocking the full commitment to hematopoietic stem cells. His work aims to provide deeper insights into blood cell formation and identify potential therapeutic targets for haematological disorders.
Top Publications
- Ng, ES, Sarila, G, Li, JY, Edirisinghe, HS, Saxena, R, Sun, S, Bruveris, FF, Labonne, T, Sleebs, N, Maytum, A, et al. Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells.. Nat Biotechnol 2024 view publication
- Maytum, A, Porter, D, de Whalley, P, Thompson, A, Plested, E, Kerridge, S, Liu, X, Smits, G, van der Klis, F, Snape, MD, et al. The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.. Pediatr Infect Dis J 43(8) : 809 -812 2024 view publication
- Coleman, DJL, Keane, P, Chin, PS, Ames, L, Kellaway, S, Blair, H, Khan, N, Griffin, J, Holmes, E, Maytum, A, et al. Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1.. iScience 27(4) : 109576 2024 view publication
- Maytum, A, Edginton-White, B, Keane, P, Cockerill, PN, Cazier, J-B, Bonifer, C. Chromatin priming elements direct tissue-specific gene activity before hematopoietic specification.. Life Sci Alliance 7(2) : 2024 view publication
- Maytum, A, Obier, N, Cauchy, P, Bonifer, C. Regulation of developmentally controlled enhancer activity by extrinsic signals in normal and malignant cells: AP-1 at the centre. Frontiers in Epigenetics and Epigenomics 2: 1465958 2024 view publication
Page 1 of 2
Career information
Share //
